Stock Details

Enter Company or Symbol. Press down arrow for suggestions, or Escape to return to entry field.

RELATED RESOURCES

Change Text Size:

BRIEF-Assembly Biosciences, Door Pharmaceuticals Sign Collaboration, Option Agreement To Develop Novel Class Of HBV Core Protein Modulators

BY Reuters
— 8:48 AM ET 11/16/2020

Nov 16 (Reuters) - Assembly Biosciences Inc (ASMB):

* ASSEMBLY BIOSCIENCES AND DOOR PHARMACEUTICALS SIGN COLLABORATION AND OPTION AGREEMENT TO DEVELOP A NOVEL CLASS OF HBV CORE PROTEIN MODULATORS Source text for Eikon: Further company coverage:

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

More ASMB News

Assembly Biosciences Presents Data from HBV Core Inhibitor Programs in Poster Sessions at the 2020 AASLD The Liver Meeting Digital Experience™
GlobeNewswire - 8:00 AM ET 11/13/2020
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire - 4:30 PM ET 11/06/2020
BRIEF-Assembly Biosciences Q3 Earnings Per Share Estimate $-0.75 -- Refinitiv Ibes Data
Reuters - 4:35 PM ET 11/05/2020